Roche’s Pirfenidone Bet Validates China Venture
This article was originally published in PharmAsia News
Executive Summary
China was probably not a major consideration in Roche’s $8 billion-plus bet on U.S. biotech InterMune and its mainstay product pirfenidone, but the figure paid for the acquisition may be seen as validation for a Chinese biotech that has already commercialized its version of the drug for IPF.
You may also be interested in...
Roche Wins InterMune, But For A Price
With the $8.3 billion purchase price, Roche gains InterMune’s sole drug, pirfenidone for idiopathic pulmonary fibrosis, pending at FDA with action expected Nov. 23.
China Could Be Third Entry For Idiopathic Pulmonary Fibrosis Drug Pirfenidone
SHANGHAI - Tokyo-headquartered GNI announced its Shanghai-based subsidiary-Shanghai Genomics has submitted a new drug application to Shanghai FDA for its TNF modulator F647 (pirfenidone) to treat patients with idiopathic pulmonary fibrosis (IPF)
BrightGene Bets On Remdesivir Amid Patent Questions
Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports